Findings showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in ambulatory 24-hour average SBP compared with placebo at week 12. Topline data were announced ...

Novel combinations and targeted pathway inhibitors may improve adherence and blood pressure control in patients with ...

Findings showed baxdrostat at both doses significantly reduced mean systolic blood pressure compared with placebo at week 12. Topline data were announced from a phase 3 trial that evaluated baxdrostat ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A U.S. flag stands next to the AstraZeneca logo during a signing event for documents related to a manufacturing site ...

The novel aldosterone synthase inhibitor baxdrostat has met its primary and secondary endpoints in the BaxHTN trial of patients with uncontrolled or treatment-resistant hypertension, according to ...

Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two ...